ZENITHDRUG

Zenith Drugs Share Price

₹83.35 -3.35 (-3.86%)

21 Dec, 2024 18:22

SIP TrendupStart SIP in ZENITHDRUG

Start SIP

Performance

  • Low
  • ₹83
  • High
  • ₹86
  • 52 Week Low
  • ₹53
  • 52 Week High
  • ₹154
  • Open Price₹85
  • Previous Close₹87
  • Volume27,200

Investment Returns

  • Over 1 Month -15.55%
  • Over 3 Month -34.06%
  • Over 6 Month + 31.36%
  • Over 1 Year + 5.51%
SIP Lightning

Smart Investing Starts Here Start SIP with Zenith Drugs for Steady Growth!

Invest Now

Zenith Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 143
  • P/B Ratio
  • 2.3
  • Average True Range
  • 4.45
  • EPS
  • 6.13
  • Dividend Yield
  • 0.6
  • MACD Signal
  • -4.12
  • RSI
  • 30.46
  • MFI
  • 22.08

Zenith Drugs Financials

Zenith Drugs Technicals

EMA & SMA

Current Price
₹83.35
-3.35 (-3.86%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹90.55
  • 50 Day
  • ₹96.99
  • 100 Day
  • ₹97.13
  • 200 Day
  • ₹86.42

Resistance and Support

83.95 Pivot Speed
  • R3 88.90
  • R2 87.45
  • R1 85.40
  • S1 81.90
  • S2 80.45
  • S3 78.40

What's your outlook on Zenith Drugs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Zenith Drugs Ltd has an operating revenue of Rs. 411.20 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 11% is healthy, ROE of 15% is good. The company has a reasonable debt to equity of 14%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 84 which is a GOOD score indicating consistency in earnings, a RS Rating of 28 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 53 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Zenith Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-05-29 Audited Results
Date Purpose Remarks
2024-09-18 FINAL Re.0.00 Final Dividend of Re. 0.5 per equity share

Zenith Drugs F&O

Zenith Drugs Shareholding Pattern

69.98%
0.42%
25.57%
4.03%

About Zenith Drugs

  • NSE Symbol
  • ZENITHDRUG
  • BSE Symbol
  • Managing Director
  • Mr. Sandeep Bhardwaj
  • ISIN
  • INE0QWN01013

Similar Stocks to Zenith Drugs

Zenith Drugs FAQs

Zenith Drugs share price is ₹83 As on 21 December, 2024 | 18:08

The Market Cap of Zenith Drugs is ₹142.9 Cr As on 21 December, 2024 | 18:08

The P/E ratio of Zenith Drugs is As on 21 December, 2024 | 18:08

The PB ratio of Zenith Drugs is 2.3 As on 21 December, 2024 | 18:08

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23